EVERSANA Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter the most to our clients and perform superior services that create value across the product life cycle.
Articles by EVERSANA Team
A New Standard for Copay Excellence: How Pharma Can Rethink Affordability
As out‑of‑pocket costs rise and insurance designs grow more complex, traditional copay models are being pushed to their limits. High‑deductible plans, accumulator and maximizer programs, and growing payer and PBM variability are fundamentally reshaping how manufacturer affordability programs operate. In a recent Q&A with Pharmaceutical Executive, Brian Laird, President, Patient Services, shares his perspective on how the copay marketplace has […]
Beyond the Pilot: Scaling the Steep Climb of AI in Drug Safety
Artificial Intelligence in pharmacovigilance often feels like a distant summit for emerging biopharma companies. Many successfully launch a pilot program only to face the harsh operational reality of scaling: crippling capital investment, a scarcity of specialized talent, and a slow return on investment. This “steep climb” can lead to pilot fatigue, forcing innovative teams to […]
Stay Ahead of Change with NAVLIN Daily’s Global Policy Watch
Pharmaceutical pricing policy has become increasingly global over the past few years, with changes happening at breakneck pace. The rise of Most-Favored Nation (MFN) in 2025 rapidly accelerated this trend, making it more essential than ever for market access professionals to have a broad view of policy developments. However, the volume, speed, and complexity of […]
Redefining the QA Role in the Age of AI
Artificial intelligence is rapidly transforming Quality Management Systems, from automating document reviews to supporting inspection readiness and risk prediction. While these innovations bring speed and scale, they also introduce new questions around oversight, accountability, and regulatory compliance. Our team at EVERSANA believes this moment represents a critical evolution in the role of Quality Assurance (QA). EVERSANA’s perspective […]
The Integrated Advantage: What Medical Affairs Needs Right Now
A New Reality for Medical Affairs Medical Affairs teams are being asked to do more, faster and with fewer resources, amid growing scientific complexity and regulatory scrutiny. The organizations pulling ahead aren’t layering on more vendors or disconnected solutions, they’re adopting an integrated model that enables clarity, speed, and consistency across the entire life cycle. Alignment is the Real Advantage for Compliance and Speed As regulatory expectations evolve […]
Solving The Rare Disease Launch Paradox — Using Pre‑Launch Planning and Partnership to Create Value
Rare disease patients cannot wait – and neither can the companies working to serve them. For emerging biopharma preparing to launch, the stakes have never been higher. Capital constraints, evolving regulatory timelines, and rising expectations from boards and investors are heightening complexity. These pressures intensify in rare disease, where traditional commercialization models become too fragmented, slow, and resource-intensive for launch teams. Discover how emerging biopharma are transforming launch performance in rare disease through an integrated commercialization partnership. This POV includes: A […]
EVERSANA’s AI Agency Platform Wins 2026 AI Excellence Award
This is the 5th Consecutive Year EVERSANA Has Been Recognized by the Business Intelligence Group for AI Innovation EVERSANA has been honored with a 2026 Artificial Intelligence Excellence Award, recognized in the Agentic AI category for our best-in-class AI Agency Platform: our end‑to‑end, enterprise‑grade system built with Google. This marks the fifth consecutive year EVERSANA has been recognized by the Business Intelligence Group for real‑world […]
4th Annual Brand Planning Report: Fueling Brand Plan Success Through AI‑Powered Integration
Cross‑functional integration and data‑driven strategy remain top priorities for brand leaders, but for many organizations, they’re still difficult to achieve. In our fourth annual report, Chief Strategy Officer at EVERSANA INTOUCH, John Kenny, and Senior Partner of EVERSANA MANAGEMENT CONSULTING, Sean Rapson, explore the state of brand planning with input from pharma marketing executives, uncovering persistent gaps in efficiency, consistency, and the ability to harness data effectively. The report outlines how an AI‑amplified, […]
Why Women’s Health Is at an Inflection Point and Why Commercialization Must Catch Up
Women’s health is undergoing a long‑overdue transformation. After decades of chronic underfunding, investment in women’s health has accelerated dramatically with capital surging more than 300% in 2018 and then tripling again between 2019 and 2024. Innovation in areas like FemTech, reproductive health, menopause, pelvic health and women‑focused chronic conditions is advancing at unprecedented speed. Yet commercialization has not […]
Webinar Recording | From MFPs to MFN: Navigating the New Rules of Drug Pricing in 2026
In this recent webinar, experts John Neal, Katya Svoboda, and David Byram examine the major policy shifts transforming the U.S. drug pricing landscape—including the accelerating impact of MFN models, evolving MFPs, PBM transparency reforms, and the growth of direct-to-patient models. The discussion highlights how these policies intersect, the risks and opportunities they create for manufacturers, […]
Gartner Is Right — About the Wrong Kind of Agency AI Platform
Gartner’s warning isn’t anti‑AI—it’s anti‑dependency. The distinction will define which agencies remain relevant by the end of the decade. A recent Gartner study predicts open-source platforms will support more than 75% of enterprise AI deployments by 2028, and their concern about CMOs getting locked into agency-controlled infrastructure is legitimate. Their concerns deserve to be taken seriously, but their analysis describes a specific type of platform […]
Advancing Medical Affairs Through Data and Scientific Communications: Key Takeaways from DIA MASC 2026
At the 2026 DIA Medical Affairs and Scientific Communications (MASC) Forum, EVERSANA shared new thought leadership focused on how medical affairs teams can strengthen decision‑making, optimize operations, and elevate scientific communications in an increasingly data‑driven environment. Through two poster presentations, our experts explored current industry practices, benchmarks, and emerging trends shaping how organizations manage medical […]
Scaling Practical AI Across Commercial Teams
EVERSANA’s AI journey began with classic predictive modeling but its evolution into an enterprise-wide strategy is rooted in something deeper: a trusted data foundation and rigorous change management. Drew McCormick, Head of Data & Analytics at EVERSANA, explains how the organization is moving from gut instinct to data-guided decisions across a diverse portfolio: from agency marketing and strategy to […]
Key Implications of Recent U.S. PBM Reforms
PBM Reform Is Here—What It Means for Manufacturers and Plan Sponsors Recent U.S. policy actions are reshaping the pharmacy benefit manager landscape. New federal legislation, a proposed Department of Labor rule, and a landmark FTC settlement are signaling increased transparency, fiduciary accountability, and enforcement across PBM business practices. While these reforms stop short of dismantling […]
Building a scalable GLP-1 care model
The rapid rise of GLP‑1 therapies has revealed a fundamental challenge across healthcare. For many patients, the pathway to their first prescription is not a single, unified entry point. It’s a maze of primary care visits, telehealth platforms, retail providers, and employer programs. The result is a fragmented experience that burdens clinicians, slows down access, and limits consistency in […]
Navigating the Intersection of AI, Global Commercialization and Patient Value
Artificial intelligence is reshaping the life sciences industry, but meaningful progress comes when technology is paired with human judgment, regulatory discipline and a clear focus on patient value. In a recent EU Startup News interview, our own Faruk Capan, Chief Innovation Officer, and Mike Ryan, General Manager, Europe, shared their perspectives on how AI is transforming global commercialization […]
Recognizing Rare Disease Day: Advancing Hope, Access and Innovation
On Rare Disease Day, we recognize the more than 300 million people worldwide living with rare conditions—individuals who often face long diagnostic journeys, limited treatment options, and barriers to consistent care. At EVERSANA, supporting this community is central to who we are and the work we do every day. How is EVERSANA advancing rare disease commercialization? […]
Why Our AI Agency Is So Much More Than ChatGPT for Life Sciences Marketing
AI is everywhere. We can generate emails, social posts, videos and research in seconds. But as Faruk Capan explains in his PM360 article, life sciences marketing requires more than a simple AI tool. It requires speed, compliance, security and human expertise working together. AI alone isn’t enough for pharma Campaigns in life sciences take time, and every delay affects patients. Tools like ChatGPT are […]
Inside the Shifting Role of Pharma 3PLs: Resilient, Regulated & Ready
Third-party logistics in the pharmaceutical industry must always be considered a strategic partnership, not a transactional handoff. Today’s 3PL is no longer about outsourcing a non-core function. It is about orchestrating a regulated, data-rich, end-to-end value chain. Danny Williams, President of Channel Management & 3PL with EVERSANA, recently was one of several experts interviewed by Pharmaceutical Commerce in their annual focus on 3PLs. As he discussed, […]
EVERSANA Recognized by Vault for the Fifth Consecutive Year
EVERSANA has been recognized by Vault for the fifth consecutive year in its 2026 Consulting Rankings, earning placement in both the: Vault Consulting 50 – North America Health Sciences Consulting category Vault’s annual rankings are informed by verified consultant feedback across the industry, reflecting perspectives on firm prestige, culture and overall experience. Consistent Recognition, Driven by Our People This continued recognition reflects the […]
Rewiring Commercialization for Biotech’s New Reality
Biotech companies are facing rapid shifts in how therapies are developed, funded and brought to market. New modalities, compressed timelines and smaller patient populations are creating pressures that traditional commercialization models weren’t designed to support. In a conversation with pharmaphorum during J.P. Morgan Week at the Informa Biotech Showcase, EVERSANA President Greg Skalicky and Precigen […]
How Pharma Marketers Can Prepare for the Next Wave of Healthcare AI
Large language model platforms are accelerating their move into healthcare. In early 2026, OpenAI launched ChatGPT Health and OpenAI for Healthcare, while Anthropic introduced Claude for Healthcare with an emphasis on enterprise safety and workflow integration. These developments signal a shift in how patients access information and how clinicians manage their day‑to‑day work. In a recent Med […]
Bringing a Breakthrough Rare Disease Therapy to Market with Rapid Speed for Patients
Launching a first‑in‑class therapy for patients, particularly in rare disease, requires more than strong clinical data. It demands speed, precision and a commercialization strategy built for complexity. Precigen’s recent FDA approval and launch of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis (RRP), offers a clear example of how emerging biopharma organizations can successfully make that transition. In a two‑part Pharmaceutical […]
Insights from Frontiers Health 2025: The Future of Commercialization Models
As the global healthcare landscape rapidly evolves, traditional launch playbooks are no longer enough. Emerging technologies, shifting pricing dynamics, and rising commercial expectations are reshaping how therapies and medical devices reach patients. At Frontiers Health 2025, experts from MENARINI Group, SpringWorks Therapeutics, and EVERSANA highlighted the growing role of artificial intelligence, digital platforms, and Direct‑to‑Disease […]
Insights from Frontiers Health 2025: How European Biotechs Can Navigate the U.S. Market
For European life sciences companies, breaking into the U.S. market means navigating one of the most competitive and complex healthcare ecosystems in the world. This topic was explored last November at Frontiers Health 2025 in a session moderated by Mike Ryan, General Manager, Europe. Featuring seasoned industry voices, the discussion highlighted both the challenges and […]
Putting Data Science in the Spotlight
EVERSANA team shares key clinical insights at industry leading events Across the pharmaceutical and life sciences industries, the need for insightful data has never been more important. To truly understand how data can transform patient care, many companies turn to trusted experts. Real-world data becomes meaningful only when interpreted through a clinical, scientific and epidemiological lens. Our Data & Analytics team applies deep medical expertise in disease mechanisms, treatment pathways and clinically relevant endpoints, while accounting for real-world care delivery systems and the interactions […]
Predicting PICO and Preparing for JCA: Insights from EVERSANA at ISPOR EU
As the EU HTA Regulation moves into implementation, Joint Clinical Assessment (JCA) is reshaping how evidence is planned and delivered across Europe. At ISPOR EU in Glasgow, EVERSANA’s Pamela Vo, VP, HEOR, joined a cross‑stakeholder panel featuring: Niklas Hedberg, Chief Pharmacist, Dental and Pharmaceutical Benefits Agency (TLV) and Co‑Chair of the EU HTA Coordination Group Michael […]
NAVLIN Daily 2025 Round-Up: The Pricing and Policy Trends Redefining Market Access
NAVLIN Daily by EVERSANA looks back at a year of rapid and often unpredictable global pricing and policy shifts that reshaped launch and access strategies worldwide. Throughout 2025, the NAVLIN Daily team supported the life sciences community with timely insights, policy and MFN tracking, and enhanced digital tools designed to help navigate an increasingly complex […]
How Pharma and PBMs Can Coexist and Lower Drug Costs Faster
The pharmaceutical industry and pharmacy benefit managers (PBMs) both play essential roles in getting medicines to patients. But years of complexity and competing incentives have strained the system. Our CEO Mark Thierer recently authored an article in Pharmaceutical Commerce, noting how meaningful progress will come not from price controls, but from a modernized model built on transparency and aligned incentives. Why Transparency Beats Price Controls Price […]
Smarter, Faster, Compliant: Our Award-Winning Our AI-Powered Solutions Recognized in PM360’s Innovation Issue
In life sciences, speed and compliance aren’t optional, they’re mission-critical. Every delay in commercialization can cost millions, jeopardize launches, and ultimately impact patient access. At EVERSANA, we’ve reimagined the commercialization model with AI-powered solutions that deliver measurable impact: accelerating workflows, reducing costs, and ensuring regulatory rigor without compromise. This commitment to innovation has earned EVERSANA recognition in PM360’s 2025 Innovation Issue, where two of our transformative […]
Digital-First Care and Affordability: Our Leaders Share Insights with pharmaphorum
Patients today expect care to be as seamless as buying online: on demand, transparent and personalized – pharma must adapt. Brian Laird, President, Patient Services, EVERSANA and Deanna Horner, SVP and Chief Pharmacy Officer, Waltz Health, explored how digital-first models, affordability and direct-to-patient strategies are reshaping the patient journey in pharmaphorum’s Deep Dive Magazine. Meeting Patients Where They Are Patients today want convenience, transparency and […]
Transitioning an Enterprise Literature Monitoring Program with EVERSANA ORCHESTRATE™ PV
How one enterprise client restored transparency and compliance in global literature monitoring Enterprise pharmacovigilance teams often face the challenge of managing high-volume literature surveillance while maintaining regulatory compliance and audit readiness. This case study highlights how a leading organization partnered with us, at EVERSANA, to transition their literature monitoring program to ORCHESTRATE™ PV—overcoming limited visibility, […]
Consolidating Data Strategy For Global Success
Data strategy isn’t just an operational detail, it’s the foundation of a successful global launch. Companies that neglect early planning risk costly missteps, from compliance gaps to duplicated investments. We believe data strategy is launch strategy. It’s what ensures evidence generation, regulatory alignment and commercial success in an increasingly complex global environment. Following our session with experts from Pulse Infoframe, Global Data Support, and IOMED at […]
New Direct-to-Employer Access Model Provides Options for Employers to Improve Access to Weight Loss Medications
Waltz Health, an EVERSANA company, has introduced a new Direct-to-Employer (DTE) Access Model for FDA-approved obesity management medicines. The model, developed in collaboration with leading drug manufactures including Eli Lilly and Novo Nordisk, gives employers a new, clinically responsible pathway to offer access to authentic GLP-1 medications with predictable pricing, end-to-end support, and real-time oversight. It […]
Pharmatizing AI: How Artificial Intelligence Is Transforming Pharma
From discovery to delivery, artificial intelligence is reshaping how pharma works—and the change is accelerating. As Global Co-Host and Presenting Sponsor of Frontiers Health 2025, our team led a critical conversation on AI in pharma. With Roberto Ascione, President of Health Innovation, as moderator, we explored what it means to truly “pharmatize” AI and how the convergence of […]
Driving Measurable Impact for Pharma Brands: How Our AI Agency Platform Improves Operational Models
Our AI Agency platform is redefining how life sciences brands approach omnichannel marketing, campaign development and so much more with unmatched speed and precision. Recently our Chief Innovation Officer, Faruk Capan, spoke with PharmaVoice about the platform and how it’s built to solve the challenges facing the industry, including the continued rise of influencers. In Faruk’s interview with PharmaVoice notes points of differentiation for […]
Brave New Commercialisation World
The pharma commercialization landscape is evolving at an unprecedented speed. At Frontiers Health 2025, our team joined industry leaders to discuss how global launches, pricing strategies and patient access are being reshaped by policy changes and innovation. Alan Crowther and Mike Ryan were onstage focusing on: Policy Shifts: How Most Favored Nations pricing is influencing […]
Google Cloud Spotlights EVERSANA: A Milestone for Pharma Innovation
When one of the world’s leading technology companies tells your story, it’s more than recognition. It’s validation of a vision that’s reshaping an entire industry. Google Cloud recently published a feature on EVERSANA’s approach to transforming pharmaceutical commercialization with the AI Agency Platform. This isn’t just about technology. It’s about how AI-powered marketing, data-driven strategies […]
Human-in-the-Loop + AI: A Pragmatic Path Forward for Pharma Commercialization
In a recent industry webinar, senior leaders from across the life sciences spectrum gathered to discuss the evolving role of artificial intelligence in commercialization. While the promise of AI is undeniable, the consensus was clear: In pharma, technology must serve as an enabler — not a disruptor — for the people who drive strategy, compliance […]
Content Acceleration Like Never Before: Meet Our AI Agency Platform
In today’s life sciences landscape, speed and precision are no longer nice-to-haves—they’re necessities for keeping pace with the needs of patients and providers and ahead of the competition. That’s why we launched the industry’s first end-to-end, AI-powered agency platform built on Google Cloud: a revolutionary model that’s transforming how brands go to market. Our AI […]
The Future of Personalized, Measurable MSL Engagement: Key Takeaways from Susan Giacalone
Not all data is equally valuable. Strategic medical insights—those that inform strategy and improve patient outcomes—are essential. In a recent article in Med Ad News (PharmaLive), Susan Giacalone explores how Medical Science Liaisons (MSLs) are redefining their value in the pharmaceutical industry. While MSLs have always been trusted partners to healthcare professionals, today’s environment demands […]
Let’s Be DIRECT: We Have An Access and Affordability Problem to Solve
Schedule a meeting to connect with one of our experts to explore whether a direct-to-patient or direct-to-provider model could be a good fit to your brand’s access and affordability strategy. The pharmaceutical industry is at an inflection point. Rising costs, opaque pricing and fragmented care are straining every part of the healthcare ecosystem. Patients, payers, […]
Navigating the New HTA Landscape: Pamela Vo on Strategic Evidence Planning
The implementation of the EU Health Technology Assessment (HTA) regulation marks a pivotal shift in how clinical evidence is evaluated across Europe. With the regulation now in effect, pharmaceutical companies face both new opportunities and new responsibilities — particularly around the Joint Clinical Assessment (JCA), a centralized process for assessing the relative effectiveness and safety […]
Disrupting the Life Sciences Commercial Model: EVERSANA Joins Insightful Conference Sessions on AI & Patient-Centric Models
Industry Thought Leaders Shape Wharton Conference On September 26, 2025, thought leaders from EVERSANA and across the healthcare, technology and life sciences industries gathered at The Wharton School in Philadelphia to participate in an exclusive scenario planning workshop – “Disrupting the Life Sciences Commercial Model: Exploring the Future Impact of AI and Patient-Centric Healthcare.” The […]
Brave New Commercialization World: Reimagining Global Launch Strategies in Life Sciences
The pace of change in global healthcare is accelerating and nowhere is this more evident than in the commercialization of new therapies and medical devices. Traditional launch strategies simply can’t keep up. Here at EVERSANA, we’re exploring new ways to navigate the complexities of launching innovations in this rapidly evolving landscape. Why Commercialization Needs a […]
AI in DTP: Turning Data into Meaningful Care Moments
In today’s healthcare landscape, personalization isn’t a luxury—it’s a necessity. In his latest article for Med Ad News, Hari Ramachandran, Executive Vice President, Direct-to-Patient Product Management at EVERSANA, explores how Artificial Intelligence is transforming Direct-to-Patient (DTP) programs from simple delivery services into deeply personalized care experiences. The article showcases how smart technology is helping patients […]
Reimagining Pharma Commercialization with AI Agents
A Q&A with Imtiaz Samjoo, EVERSANA, and Kevin Kallmes, Nested Knowledge. EVERSANA and Nested Knowledge have teamed up to revolutionize systematic literature reviews (SLRs) using AI. Their collaboration is streamlining workflows and unlocking faster, more precise insights. We sat down with Imtiaz Samjoo, Vice President, Evidence Synthesis, EVERSANA and Kevin Kallmes, CEO, Nested Knowledge, to […]
A Deeper Dive into Pharmatizing AI & What It Will Mean to the Future of Commercialization
For the past 4 years, we have talked about our commitment to “Pharmatize AI” to deliver true change for the industry. The time to lead is now. We’re at a transformation moment where, through the power of technologies, partnership and experts, we are changing an industry. So, what does pharmatizing AI look like? It looks […]
The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts
The 340B program has struggled with implementing effective oversight of the covered entities since the program was established in 1992. Diversion and duplicate discounts are the primary issues that manufacturers face. Diversion typically happens when a 340B drug is dispensed to a non-340B patient and duplicate discounts typically happen when a product receives a 340B […]
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
CMS released its 2026 Proposed Rule this summer, outlining payment and coverage policy updates for Medicare Part B and related programs. For pharmaceutical manufacturers, the most significant development is the long-awaited clarification on bona fide service fees (BFSFs). If finalized, these provisions will place new compliance demands on manufacturers. Although primarily focused on Average Sales […]
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was signed into law, marking a significant shift in Medicaid, Medicare, and federal drug pricing policy. While broad in scope, its provisions have direct consequences for pharmaceutical manufacturers—especially those participating in government programs. Looking at only a few of these new regulation shifts, it becomes […]
Rewriting the Rules of Pharma Commercialization: Why the AI Agency Is the Catalyst Life Sciences Has Been Waiting For
Scientific innovation is accelerating. But commercialization? It’s stuck in the past — fragmented, reactive and increasingly unsustainable. Learn why the AI Agency is the catalyst life sciences commercialization has been waiting for in this POV. Faruk Capan, Chief Innovation Officer at EVERSANA, lays out a bold new vision for life sciences leaders: a future powered by agentic […]
Navigating the New EU HTA Landscape: Pamela Vo on Strategic Evidence Planning
In a recent pharmaphorum interview, EVERSANA’s Pamela Vo emphasized the importance of early strategic evidence planning under the EU’s new Health Technology Assessment Regulation (HTAR). With the Joint Clinical Assessment (JCA) streamlining clinical evaluations across member states, companies must align regulatory, clinical, and market access strategies from the start. Key takeaways: Early PICO forecasting is […]
EVERSANA & Google Cloud Bring AI Agency Concept to Life
EVERSANA is redefining the future of medical marketing with the launch of its groundbreaking AI Agency—an end-to-end solution developed in partnership with Google Cloud. This platform, unveiled at Google’s New York office recently, promises to deliver what traditionally takes months in mere minutes, transforming how pharma brands approach strategy, omnichannel engagement, and content creation. Unlike […]
Navigating MFN: Alan Crowther on What Pharma Brands Must Know Now
As the pharmaceutical industry grapples with the implications of the Most Favored Nation (MFN) Executive Order, Alan Crowther, General Manager of Global Pricing & Market Access Solutions, offers timely insights into what this directive means for brand strategy and innovation. In a recent interview with Pharmaceutical Executive, Crowther breaks down the latest MFN directive—a letter […]
Repairing the Patient Journey: How Pharma Can Fix the Obvious – and Not So Obvious – Breaking Points of Nonadherence
When nearly half of all treatment failures stem from nonadherence, the stakes for patients, and for pharma, could not be higher. One of the most persistent barriers in healthcare, leading to preventable hospitalizations, lost lives and billions in avoidable costs each year, is patient nonadherence. The reasons are complex, ranging from access and affordability challenges […]
From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services
Patients today too often find themselves navigating a myriad of challenges that can make accessing quality healthcare a daunting task. Common obstacles range from financial barriers to long wait times to geographical and technological limitations and much more Direct-to-Patient (DTP) models are emerging as a powerful solution. By treating patients as consumers, DTP models streamline […]
AI + RWE: Powering Smarter Patient Solutions
Artificial intelligence is transforming how we use real-world evidence (RWE) to improve patient care. As highlighted in Med Ad News’s online edition, pharmalive.com in the article, “AI backs up RWE”, machine learning is helping uncover patterns in vast healthcare datasets—accelerating diagnoses, personalizing treatments, and enhancing decision-making. EVERSANA is at the forefront of this shift. From […]
Reimagining Drug Safety: A New Era of Innovation
In a rapidly evolving healthcare landscape, the need for smarter, faster, and more scalable pharmacovigilance (PV) solutions has never been greater. In a recent interview with Pharmaceutical Executive, Vikram Anand shares how EVERSANA is meeting this challenge head-on with the launch of EVERSANA ORCHESTRATE™ PV—a bold, AI-powered platform designed to simplify and accelerate drug safety operations. From […]
Unlocking the Future of Medical Information Analytics: A Q&A with Michael DeLuca of EVERSANA
EVERSANA’s recent collaboration with 3VUE is reshaping how medical information interactions and metrics are analyzed and visualized to demonstrate value and impact. We sat down with Michael DeLuca, Executive Vice President of Global Medical Affairs & Medical Information at EVERSANA, to explore the vision behind the partnership and the value it brings to clients and […]
Insights from BIO with OS Therapies
At this year’s BIO International Convention 2025, pharmaphorum’s Jonah Comstock sat down with Paul Romness, CEO of OS Therapies, and Farah Ahmad, VP of Business Development at EVERSANA, to explore how emerging biotech companies are navigating today’s volatile landscape—and why global collaboration is more critical than ever. In the interview, Romness shared OS Therapies’ mission […]
Case Study: Transforming Market Access with NAVLIN Insights KPI
How one global pharma team turned fragmented pricing data into strategic power. In a complex launch environment, pricing and market access teams face mounting pressure to deliver insights that resonate with CEOs, affiliates, payers, and investors. This case study reveals how a leading oncology organization partnered with EVERSANA to overcome data silos, manual reporting, and […]
Pharmatizing AI & EVERSANA’s Bold Vision for Its AI Accelerator
EVERSANA continues to redefine the future of pharmaceutical commercialization with its newly launched AI Accelerator—a dedicated center of excellence designed to embed artificial intelligence across every touchpoint of the life sciences value chain. Spearheaded by Chief Innovation Officer Faruk Capan and Chief Digital Officer Scott Snyder, the initiative aims to “pharmatize AI”—applying cutting-edge technology in […]
Where Process Meets Profit: How Strategic Order to Cash Drives Real Revenue Outcomes
Is your Order to Cash (OTC) process helping you maximize revenue—or quietly leaking it? In their latest article, EVERSANA experts Christina Christos and Jim Burke explore how pharmaceutical manufacturers can align OTC and Revenue Management to eliminate operational blind spots, reduce deductions and improve gross-to-net performance. It breaks down why real-time collaboration, a single source […]
Reimagining Patient Health Experiences: A New Paradigm for Transforming Lives
Traditionally, the healthcare system has approached patient care, especially for those with acute conditions and rare diseases, through a lens of sympathy, problem-solving, and normalization. The focus has often been on identifying deficits and developing tools or treatments that help patients “cope” or “manage” their conditions. While these efforts are well-intentioned, they implicitly reinforce a […]
Most Favored Nation Pricing | Insights and Implications for Manufacturers
The EVERSANA MANAGEMENT CONSULTING team provides an overview of the recent developments and shares their views on the strategic implications for manufacturers. Manufacturers must act decisively to mitigate Most Favored Nation (MFN) exposure through global pricing strategy, stakeholder engagement, and confidential contracting. Develop evidence dossiers for therapeutic value and negotiation leverage Participate in CMS public […]
Demystifying Market Access: A Must-Read for Navigating the Lab-to-Patient Journey
Market access is no longer just a final hurdle—it’s a strategic imperative that shapes how therapies reach the patients who need them most. If you’ve ever wondered what it really takes to bring a treatment from the lab to the lives it’s meant to change, this article is for you. In Pharmaphorum’s latest Deep Dive, “Demystifying Market […]
EVERSANA Returns as Global Host and Presenting Sponsor for Frontiers Health 2025
Building on its commitment to global health innovation and bringing innovators together from around the globe, EVERSANA returns as the Global Host and Presenting Sponsor of Frontiers Health 2025, which will take place November 11-12 in Berlin. 2025 marks the 10th anniversary of Frontiers as one of the world’s premier health innovation conferences. CEO Jim […]
CASE STUDY: Transforming Clinical Trials with EVERSANA
Modernizing Clinical Trials to Accelerate Access Clinical trials are essential for bringing life-changing therapies to market, yet traditional models often present significant barriers for both participants and trial sites. A leading pharmaceutical manufacturer partnered with EVERSANA to revolutionize their trial process, addressing inefficiencies, enhancing accessibility and expediting results. Conventional clinical trials require frequent in-person visits, […]
Beyond Clinical Trials: Real-World Evidence Illuminates the Value of First-Line CDK4/6i in Metastatic Breast Cancer
While randomized controlled trials (RCTs) have been instrumental in establishing new standards of care, a comprehensive understanding of treatment effectiveness requires insights from real-world evidence (RWE). This is particularly true in the evolving landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (A/MBC), the most commonly diagnosed subtype globally. The introduction […]
Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth
As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market […]
Case Study: Increasing Product Adoption Rate through EVERSANA’s Digital Hub Portal
Problem: Our client launched a new product in the U.S. market, but initial adoption rates were disappointingly low. Physicians, who were eager to incorporate this innovative product into their practice, hesitated to prescribe from the complexity of the reimbursement process. Solution: To address these challenges, we deployed our digital hub portal to provide coverage and […]
The End of the Blockbuster: Adapting to a New Pharmaceutical Landscape With a New Commercialization Model
Traditional commercialization strategies that once fueled massive growth and profitability are no longer viable in today’s complex and competitive market. High SG&A costs without resulting revenue, patent cliffs, rising patient acquisition costs, convoluted supply chain management, fragmented execution, lack of pricing transparency, and complicated relationships with PBMs are some of the internal and external pressures […]
EVERSANA Wins AI Excellence Award for 4th Straight Year, Building on Legacy of Innovation
Company recognized in 2025 for AI-Powered HCP Panels Used for Sales Representative Training Innovation is in the lifeblood of EVERSANA. And so, when the 2025 AI Excellence Awards winners were announced, it was not surprising that once again EVERSANA made the list. This year the company was recognized in the product category for its work […]
Overcoming the Odds: How EVERSANA Helped a Family Navigate Their Rare Disease Journey
A Rare Diagnosis and the Start of a Family’s Courageous Journey For families navigating the complexities of a rare disease diagnosis, the path can be filled with uncertainty, challenges and moments of profound resilience. One such family’s journey underscores the importance of expert care, unwavering support and innovative therapies that transform lives. From an early […]
Rare Disease Care in India: A Path to Positive Impact
India’s rare disease market is on the rise, expected to grow from $2.74 billion to $6.6 billion by 2030. However, challenges such as delayed diagnoses, limited treatment accessibility and underutilized government funds continue to impact patient outcomes. This article from explores the current landscape of rare disease management in India, highlighting key policies like the […]
The AI Revolution: 7 Trends Shaping the AI Revolution in 2025
We’re just weeks into 2025, and already, the landscape of artificial intelligence (AI) continues to evolve at an unprecedented pace, reshaping industries and redefining possibilities. In the realm of healthcare, AI is not just a buzzword; it’s a transformative force driving innovation, efficiency, and personalization. From direct-to-patient models to AI-powered medical devices, the integration of […]
Point-of-Care (POC) Diagnostics: Transformation From Pre- to Post- Pandemic: An Asian Perspective
Authors: Dr. Shaillender M, Engagement Manager, EVERSANA APAC; Robin Arnold, Executive Vice President, EVERSANA APAC; Aditya Prakash, Consultant, EVERSANA APAC The pandemic significantly accelerated the adoption and technological advancement of point-of-care (POC) diagnostics, transforming them from niche applications to common household tools. This POV document explores the evolution of POC diagnostics, highlighting three key categories: […]
Think Tank 2025 Pharma Forecast: What Lies Ahead for the Industry in 2025?
The pharmaceutical industry is poised for a transformative evolution by 2025, driven by the possibilities of emerging technologies, regulatory shifts, personalized medicine, and lessons from recent global crises. Together, these trends will redefine the pharmaceutical landscape, setting a new standard for innovation, collaboration, and patient-centered care. PM360 asked specialists about what they believe the New […]
From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services
Patients today too often find themselves navigating a myriad of challenges that can make accessing quality healthcare a daunting task. Various common obstacles range from financial barriers to long wait times, to geographical and technological limitations and much more. In light of all of these complexities, it’s crucial to understand the specific hurdles patient services […]
Insight from Frontiers Health: Harnessing Machine Learning to Transform Clinical Outcomes
Our Chief Medical Officer, Dr. Pierantonio Russo, joined on stage at Frontiers Health 2024 to discuss the impact of Machine Learning (ML) on healthcare, particularly in predicting hospital readmissions and managing chronic diseases. In this session, he highlighted a real-world study on using predictive models to identify patients with diabetes and COPD who need continuous […]
The Promise of Direct-to-Patient – What’s Really Needed for Patient Access
In today’s healthcare landscape, patients are no longer passive recipients of care. They are empowered, tech-savvy stakeholders who demand efficiency and transparency. Yet, despite advancements in consumer innovation, the healthcare system often leaves them frustrated with delays and outdated workflows. Imagine a world where patients can swiftly access the right specialists, understand complex therapies, and […]
The Increasing Role of AI in Improving the Diagnostic Imaging Landscape
Discover how artificial intelligence is revolutionizing the medical imaging landscape in our latest white paper, “The Increasing Role of AI in Improving the Diagnostic Imaging Landscape.” This comprehensive guide explores: Enhanced Diagnostic Accuracy: Learn how AI reduces errors and improves precision in interpreting X-rays, MRIs, CT scans, and PET scans. Improved Time Efficiency: See how […]
Insights from SAHARA+ Conference: Harnessing Real-World Data and AI to Transform Healthcare
EVERSANA’s executive director and Middle East head, Prashant Pandarathil, recently presented at Saudi Arabia’s Healthcare Advancement for Resourceful Funding, Regulatory Excellence and Innovation (SAHARA+) Conference on the topic “Harnessing the Power of Real-World Data (RWD) and AI in Healthcare.” Here are some key takeaways: The integration of RWD into healthcare offers significant benefits, ranging from […]
Finding the Human Element Amid the Algorithms
The programmatic buying and selling of health media is, ultimately, steered by the humans that enable it. So why does the notion that it’s a machine-driven process still linger? Spend more than a few minutes of time talking with heads of the programmatic media desks at pharma companies and their partner agencies, and you’ll hear […]
3 Questions You Need to Answer Before Partnering With Integrated Delivery Networks
Are you a pharmaceutical manufacturer looking to navigate the complex world of Integrated Delivery Networks (IDNs)? These powerful entities, which manage multiple healthcare facilities, are key players in delivering high-quality, cost-effective, and patient-centered care. But how can you effectively engage with them to drive sales and support patient outcomes? In our latest white paper, “3 […]
Digital Therapeutics: A Necessity for Italy – Insights from Roberto Ascione and Alberta Spreafico
A Collaborative Approach to Integrating Digital Therapeutics (DTx) into the Italian Health System Roberto Ascione, our President, Health Innovation, and Alberta Spreafico, PhD, MBA, Senior Vice President, Health Innovation, have co-authored the Italian publication “Digital Therapeutics: A Necessity for Italy.” This work continues the journey initiated in 2019 with the project “Terapie Digitali per l’Italia” […]
Enhancing Patient Adherence and Sales Outcomes in Advanced Prostate Cancer Treatment Through Proactive Push Alerts
Data and analytics play a crucial role in developing patient adherence programs by providing actionable insights and enabling data-driven decision-making. Through our latest case study, see how this information was used to develop tailored push alerts that not only improved patient adherence but also boosted market share and sales outcomes for a new six-month dosage […]
Understanding Key Reforms for High-Cost Drugs in EU4+UK Markets
Are you interested in the latest developments in high-cost drug reforms across the EU4+UK markets? Our comprehensive paper, “Understanding Key Reforms for High-Cost Drugs in EU4+UK Markets,” delves into the intricate landscape of pharmaceutical pricing and reimbursement. With the rising costs of innovative therapies and an aging population driving demand, each country within the EU4+UK […]
Tumor Types Drive Oncology Product Launch Strategies
Unlike traditional launch plans designed for blockbuster products, oncology and hematology therapy commercialization requires agility. Different tumor types and the form of therapy require distinct commercialization strategies. Patients with lung, breast, or colon cancer often undergo long-term, multi-faceted treatment following early detection, requiring sustained patient services and financial support. In contrast, pancreatic cancer patients typically […]
EVERSANA Experts On-Stage at Frontiers Health 2024
In anticipation of Frontiers Health 2024, EVERSANA is delighted to reveal that several of our key experts will be speaking at this top-tier global health innovation conference! Scheduled for October 17-18th in Berlin, Germany, Frontiers Health 2024 is set to focus on digital therapies, breakthrough technologies, healthcare transformation, investments, and ecosystem development. The event brings […]
EVERSANA’s Predictive Analytics: A Capabilities Compendium
In the fast-changing world of healthcare, machine learning (ML) and real-world evidence (RWE) bring us closer to the goal of precision medicine: delivering the right treatment to the right patient by the right physicians at the right time. EVERSANA is proud to introduce this collection of case studies that demonstrate the transformative power of ML […]
Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky
Integrated Delivery Networks have impacted everything from drug launches to sales approaches. Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, President at EVERSANA, spoke with Pharmaceutical Executive about the ways that commercialization teams are working with these networks to bring drugs to markets. Pharmaceutical Executive: How are IDNs being […]
EVERSANA’s Commitment to Health Innovation in Europe: Leading the Charge at Frontiers Health 2024
EVERSANA is leading conversations about next-generation commercialization as the presenting sponsor at the global health innovation event Frontiers Health 2024. As we expand our global reach in Europe and beyond, Frontiers Health represents the perfect event for EVERSANA to be a part of as the presenting sponsor. During the two-day conference, ecosystem leaders, founders, C-suite […]
AI’s Role in Drug Launches, Operations, and Drug Pricing: Q&A with Abid Rahman
Over the past year, AI-powered technology has become more and more commonplace across the pharmaceutical industry. Abid Rahman, senior vice president of innovation at EVERSANA, spoke with Pharmaceutical Executive about some of the various sectors where the technology has been introduced and how it’s working. Pharmaceutical Executive: How is AI being utilized for product launches? Abid […]
EVERSANA Named Global Host and Presenting Sponsor of Frontiers Health 2024, Bringing Innovators Together Across Europe and Beyond to Transform Healthcare
Today EVERSANA, a leading provider of global commercial services to the life sciences industry, is proud to announce that we will be the global host and presenting sponsor for Frontiers Health 2024. The two-day event, which brings together health leaders from around the world to discuss new technologies, policy, health equity and other concepts that […]
Report: Integrated Delivery Network Trends and Engagement Strategies Every Drug Manufacturer Needs to Know
Unlock the full potential of your Integrated Delivery Network (IDN) strategies with EVERSANA’s latest Market Research & Insights Report. Drug manufacturers are engaging with IDNs to address pain points and trends, optimize patient outcomes, and foster value-based care through innovative solutions. Dive into a detailed analysis of the latest trends and strategies within the IDN […]
Strategic Launch: Accelerating Innovative Therapies in the Chinese Market
Given the recent business and sociopolitical environments, having the right business model is critical to successfully entering the China pharmaceuticals market. In this webinar, we will share relevant examples regarding how other life science companies responded to the various business environmental changes in China and discuss how European pharmaceutical companies can enter the China market successfully […]
Market Access and the Inflation Reduction Act
The Inflation Reduction Act of 2022 (IRA) institutes Medicare changes that include the ability to negotiate drug prices, limit price increases and cap out-of-pocket costs for beneficiaries. Understanding the far-reaching implications of these provisions is crucial for market access professionals to successfully navigate the new dynamics and plan for success in the future. In this […]
Optimizing Patient-Centered Care: Strategies for Improving Health Outcomes
With a rapidly evolving health insurance landscape in India, it is imperative to understand the challenges and potential solutions for innovative medical technologies reimbursement by private health insurance in India. EVERSANA recently partnered with St. Jude Medical India Pvt. Ltd. (now Abbott) to conduct a roundtable discussion with private insurance stakeholders on “Optimizing Patient-Centered Care: […]
Integrated Delivery Networks (IDNs): Driving Change in Drug Access and Utilization
As of May 2024, a striking 77.6% of physicians in the United States are employed by hospitals, health systems and corporate entities – a significant surge from less than 50% a mere decade ago. This trend underscores a seismic shift in healthcare delivery, as practitioners increasingly opt to join Integrated Delivery Networks (IDNs). While the […]
Equip FRMs with the Right Tools to Unlock Patient Access
In the modern healthcare landscape, multiple daunting challenges muddy pharmaceutical manufacturers’ ability to ensure patients have timely and uncomplicated access to high-quality care and life-altering medications. A plethora of obstacles can impede the processes of finding an appropriate HCP or specialist, receiving a diagnosis and obtaining proper treatment. Because the patient journey can present numerous […]
Pioneering the Path: How Medical Affairs is Charting the Course for Pre- and Post-Launch Strategies
Early involvement of Medical Affairs in the product lifecycle is not just beneficial – it is mission critical. In the swiftly changing realm of advanced therapies like biosimilars, rare disease molecules, and cell and gene therapies, a strong scientific interpretation and orientation is essential. Medical Affairs teams are stepping up to this challenge, actively shaping […]
Q&A: Enhanced Protection and Consistency for PRCI in Canada
Introduction At EVERSANA, we’re at the forefront of regulatory work in Canada, and recently, our team has been delving into the realm of PRCI (Public Release of Clinical Information) in Canada and submission Policy 0070 (Regulation EMA (EU) 536/2014) in Europe). Understanding PCRI What is PRCI, and Why Does it Matter? PRCI stands for Public […]
Navigating Successful Partnerships in the Pharmaceutical Industry: Insights from Shorla Oncology CEO Sharon Cunningham
In the ever-evolving landscape of the pharmaceutical industry, forging successful partnerships and collaborations is a cornerstone of achieving groundbreaking advancements and bringing innovative treatments to patients in need. However, navigating through the myriad of advisors, consultants and potential collaborators can be daunting for even the most seasoned professionals. Enter Sharon Cunningham, CEO and Co-Founder of […]
CES 2024 Recap – How the Future of Healthcare Will Continue to Be Driven By Innovation & AI
CES 2024, the annual tech conference encompassing everything from cutting-edge gadgets to automotive marvels, healthcare innovations, and futuristic media, left a lasting impression. Amidst the buzz surrounding electric vehicles, transparent screens, and an abundance of massage chairs (so many massage chairs), there was one technology that overlapped across all: AI. The rapid integration of AI […]
Embarking on the Care Journey: Strategies for Engaging Patients Pre- and Post-Diagnosis
Navigating the healthcare system is a complex task for any patient, but it can be particularly tricky for those who are searching for more information on their symptoms, grappling with a recent diagnosis or looking for a particular type of care for the first time. Finding an appropriate specialist or treatment option and accessing relevant […]
Impact of the European Union Medical Device Regulation Extension on Legacy Devices
Question: The European Union (EU) has extended the transition period for medical devices under the Medical Device Regulation (MDR) and removed the sell-off provisions for existing products. How do these changes impact you? Answer: On 7 March 2023, the European Council voted to adopt a measure to extend the transitional period for medical devices under […]
The Hospital of the Future and How Data, Digital and AI Merge to Make Care Better
By Pierantonio Russo, MD, FCPP, FAAP, STS, Chief Medical Officer, EVERSANA In the fast-paced realm of healthcare, innovation stands as the cornerstone of progress. Recently, I had the privilege to attend Frontier’s Health , a leading gathering of some of the best minds in the world to discuss how to shape the future of health […]
The Data-Driven Revolution: AI’s Impact on Pharmaceutical Quality in Digital Therapy
In the intricate web of pharmaceuticals, a groundbreaking transformation is underway – one that marries data analytics with digital therapy, reshaping the industry’s landscape fundamentally. As the dust settles from the FDA Symposium, a seismic shift in focus becomes apparent: the integration of Artificial Intelligence (AI) in Digital Therapy isn’t just a trend; it’s a […]
Navigating the Evolving Landscape of Internet Healthcare in China: Development Status, Challenges, and Future Prospects
Authors: Robin Arnold, Executive Vice President; Renyang Liu, Engagement Manager; Erica Wang, Associate Consultant Background Internet healthcare means using the internet to provide health and medical services. China has implemented “Internet Plus Healthcare” as a national policy, as a part of reforming the healthcare system. Internet healthcare in China is estimated at 150 billion RMB […]
Unveiling the Future: AI Opportunities in FDA Compliance, Insights from the OPQ Symposium
In the dynamic realm of pharmaceuticals, staying ahead of the curve is not just an advantage; it’s a necessity. Recently, our team had the privilege of attending the CDER’s Office of Pharmaceutical Quality (OPQ) symposium, where the focus was on a topic that’s transforming the industry: Artificial Intelligence (AI). As consultants deeply involved in FDA […]
Driving Patient-First Affordability in Seconds – Not Days: Accelerating Time to Therapy
Fewer than 60% of Pharmacy Benefit Manager (PBM) electronic benefit verifications (eBVs) accurately assess patients’ financial responsibilities, largely due to the industry’s reliance on AI algorithms for estimations. This leads to financial barriers for patients, hesitancy among healthcare providers (HCPs) to prescribe therapy, and increased burdens on Patient Assistance Programs (PAP) and Hubs. In this […]
APACMed Digital Health Reimbursement Policy Forum
Introduction The APACMed Policy Forum on Digital Health Reimbursement was held on 23 May 2023, with participants from Australia, Japan, Singapore, South Korea, Germany, France, and the UK. Several digital health policymakers, academicians, and experts from the respective countries, along with the APACMed Digital Health Reimbursement Alliance (DHRA) core committee, local trade associations, and EVERSANA […]
New Models of Benefits Verification Solve for Complexity, Accelerate Speed to Therapy and Deliver Price Transparency
Navigating health care insurance coverage can be a supremely convoluted process for anyone, especially patients or caregivers recently faced with coping with a life-threatening disease. While the advancement of many new treatments and scientific innovations in the form of “specialty drugs” has been invaluable in treating complex diseases, these conditions often muddy the benefit verification […]
Unlocking Global Success: The Crucial Role of Integrated HEOR Programs in New Product Launches
Author: Kirk Szafranski, Director, HEOR, Value & Evidence Health Economics and Outcomes Research (HEOR) programs play a pivotal role in assessing a product’s value, cost-effectiveness, and real-world impact on patient outcomes, which are critical factors influencing reimbursement decisions, formulary placements, and overall market access. A global integrated HEOR program typically includes a range of components […]
The Rising Demand for Light Medical Aesthetic in China
“The Rising Demand for Light Medical Aesthetic in China” provides a captivating insight into the surging popularity of non-surgical medical aesthetics in China. The article highlights the rapid growth of the medical aesthetic market and the shifting trends in consumer preferences. It delves into the key contributors and experts driving this industry and examines the […]
Revolutionizing Vaccines: The Rise of mRNA Technology in China
Key Contributors: Robin Arnold, Executive Vice President; Renyang Liu, Engagement Manager; Nicole Li, Analyst Discover how mRNA technology is transforming the field of vaccines in China. From the evolution of vaccine development to the rapid progress of mRNA vaccines during the COVID-19 pandemic, this article explores the advantages of mRNA vaccines compared to conventional ones. […]
Maximizing Potential: Essential Steps for Successful Commercialization of Cell and Gene Therapies
Introduction Cell and gene therapy (CGT) products have significantly enhanced the quality of life for millions of patients impacted by medical conditions that are untreatable with traditional medicines or surgeries such as certain cancers, inherited and rare diseases, and intractable conditions. As these therapies continue to propel groundbreaking advancements in remedying previously incurable diseases, the […]
The Art of Simplifying Pharmacovigilance – Part I: Connecting the Dots
The Art of Simplifying Pharmacovigilance – Part I: Connecting the Dots In the intricate realm of pharmacovigilance, there is an art — a delicate dance of connecting the dots. Like a skilled painter, vigilant professionals adeptly simplify the complex web of drug safety, linking scattered points to reveal a cohesive picture. With unwavering focus, they […]
Commercial Key Success Factors (KSFs) for Global Drug Development Programs
Key Contributor: Robin Arnold, Executive Vice President Discover the essential commercial key success Factors (KSFs) that drive triumph in global drug development programs. In an era of diverse regulatory perspectives and reimbursement complexities, biotech companies face higher stakes than ever before. Swapnil Waichale and Robin Arnold unveil the top failure modes for biotech firms and present […]
Specialty Pharmacies are Ready for the Biosimilar Boom. Are you?
The pharmacy benefit biologic market is primed for disruption, with Specialty Pharmacies (SPs) eagerly awaiting the pending market shift. While biosimilars have been available for nearly a decade in the United States, this year will be the first time many SPs begin dispensing these brands. Currently, 22 biosimilars are available in the U.S. and, up […]
Position Your Future-Facing Strategy on Digital Therapeutics (DTx) in China
How can DTx resonate with current portfolios and capture incoming opportunities? Key Contributors: Robin Arnold, Executive Vice President; Jerry Song, Associate Principal; Qiwei (Alex) Li, Consultant The article discusses the potential of digital therapeutics (DTx) in China’s healthcare system and how it can help pharmaceutical and medical technology companies address the challenges presented by the country’s aging […]
Forecasting in the Age of Value-Based Agreements
The pharmaceutical industry faces a host of increasingly complex challenges and critical decisions when attempting to manage and predict their products’ plausible revenue patterns. The mishandling of revenue forecasting and evaluation can result in substantial financial liabilities, which has become more of an issue for manufacturers as products, disease states and additional factors that previously […]
Key Considerations When Operationalizing Revenue Management
Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’ gross-to-net. But how and where to invest valuable assets is a significant decision. The process of revenue management, including […]
Digital Guide to Commercializing Complex Therapeutics
Pharmaceutical manufacturers specializing in Rare Disease, Oncology, Personalized Cancer Immunotherapy, and Cell and Gene therapies encounter a range of complex challenges, including advancements in medicine and technology, changing patient and provider needs, market access, regulatory pathways, pricing transparency, patient reach, patient adherence, and ever evolving disease states. Despite spending over $200 million on product launches, […]
Unlocking Success: Exploring Critical Factors for Launching Orphan Drugs
A Conversation with Ashley Cox, Senior Principal, Head of Europe, EVERSANA MANAGEMENT CONSULTING, and Sid Agrawal, Senior Principal, EVERSANA MANAGEMENT CONSULTING Join Ashley Cox, Senior Principal and Head of Europe, and Sid Agrawal, Senior Principal, as they delve into the realm of orphan drugs. With 6,424 designations granted since 1983 and 1,085 products receiving FDA […]
Past and Present U.S. Public Health Laws and Regulations, and Their Impact on the Corresponding FDA Regulated Products and Industries
To be regulated by the FDA, foods, cosmetics, human and animal drugs, biologics, tissues, medical devices, combination products, and tobacco products have to meet the federal public health definitions. This white paper provides an overview of past and present U.S. public health laws and regulations and their impact on FDA-regulated products and industries. It highlights the […]
Pricing Complexities of a Combination Therapy
This article, authored by EVERSANA’s Asia Pacific team, discusses the increasing use of combination therapies in oncology and the challenges associated with pricing them. Combination therapies, which involve a backbone therapy and one or more add-on therapies, offer better clinical outcomes but pose difficulties in determining their value and pricing. One challenge arises from the fact […]
Integrating the Pillars of Global Pricing Governance
How Emerging Trends are Demanding a More Holistic View to Drive Maximum Value As the complexity of investments needed to secure patient access to therapy increases, so does the impact of these investments on a company’s net revenue. Each decision needs scrutiny, not only on its own merits and how it can affect patient access […]
Seven Challenges Traditional Omnichannel Tactics Cannot Overcome
How pharma companies utilize omnichannel is a significant factor in their brand’s success, especially as traditional efforts continue becoming more and more obsolete and rejected by patients and providers. Many manufacturers are facing pivotal decisions about what direction to go in with their omnichannel efforts, and whether to embrace new innovative techniques. In this article, […]
The Future of Omnichannel is Here. Don’t Get Left Behind.
The standard for omnichannel continues to evolve whether pharma companies like it or not. A next-gen approach to this crucial component of the patient journey is essential to maximize success and best optimize valuable assets. In this article, learn how redefining omnichannel efforts does not have to require investing additional resources. Instead, companies can adapt […]
Create a Comprehensive Experience by Optimizing Forward-thinking Omnichannel Strategies
Deploying successful omnichannel strategies requires manufacturers to evaluate their tactics and ensure they are meeting patients’ and providers’ needs in a modern and effective way. In this article, we lay out a check list of criteria for manufacturers to incorporate into their omnichannel strategy for heightened results that will elevate their brand among competitors, best […]
Navigating an Ever-evolving Canadian Market Access and Reimbursement Environment
These are just some of the trends currently shaping the Canadian market access environment. Achieving favourable market access and reimbursement outcomes for new treatments in this ever-changing landscape requires intimate knowledge of the Canadian landscape, processes and key stakeholders, careful strategic planning, sound tactics and skilled execution. Some key steps and considerations to maximize the […]
2023 Outlook Of China Healthcare Industry: Remaining Pragmatic While Moving Up The Value Chain
As we enter 2023, China surprised the world with a swift and decisive shift in COVID policy, demonstrating the country’s ability to be flexible and pragmatic in its decision-making. In contrast to Russia’s persistent adherence to ideologies, China demonstrated its willingness to pivot quickly when necessary. The 14th Five-Year Plan at the 20th National Congress […]
Left-Right-Left: The Latest in Pharma-Payer Ping Pong
Biopharmaceutical companies have offered financial assistance for commercially covered patients’ out-of-pocket (OOP) cost sharing for 20+ years. However, in the ongoing evolution of controlling versus encouraging patient access to specific drugs, payers and biopharma also have a long history of one-upmanship. Are pharma motivations for offering copay assistance centered on the patient, their own bottom […]
Employ an Integrated Market Access Strategy to Deliver Brand Success
The pharma/life sciences pipeline is vibrant, with ongoing innovation bringing new hope to patients and providers across many therapeutic areas. Against the backdrop of rapid scientific advancement in and precision medicine and targeted therapies in primary and specialty care as well as rare and orphan diseases, today’s medicines continue to create immense complexity for all […]
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
EVERSANA’s Value & Evidence (V&E) and Data & Analytics (D&A) team collectively had an impressive 27 abstracts accepted to ISPOR U.S. 2023, showcasing EVERSANA’s ability to cross-solve for clients’ HEOR needs. EVERSANA’s Value & Evidence and Data & Analytics teams have had 27 abstracts accepted to ISPOR U.S. 2023, the leading global conference for health […]
Use of Machine Learning to Accurately Size Market Potential and Optimize Sales and Marketing Resources
Machine Learning as a strategic lever in healthcare. Recent advances in Machine Learning (ML) now make it possible for pharmaceutical companies to more accurately identify patient populations, including misdiagnosed patients with rare diseases and other diseases that have a high prevalence of symptomatic related diagnoses, along with their healthcare providers. With this knowledge, it also […]
Case Study: Optimizing use of Field Reimbursement Managers
Navigating the complexities of insurance coverage can be a time consuming and challenging task. Field Reimbursement Managers (FRMs) were introduced as a way to help healthcare providers address issues or challenges related to securing timely access to treatments for patients, and for securing timely and appropriate reimbursement for therapies that the practice must purchase and […]
Case Study: Waste Reduction through Packaging Optimization
Pharmaceutical companies are being challenged to develop more effective delivery mechanisms of their therapies in order to reduce the amount of product waste. Recent changes in legislation, including the Waste Reduction Act of 2022 and adoption of Section 1847A of the Social Security Act have made it critical for pharmaceutical companies to optimize drug packaging […]
Filling the Missing Spaces in Your Network Meta-Analysis: The Role of Surrogate Models
Network Meta-Analysis Network meta-analysis is a statistical method that combines data from multiple randomized controlled trials to compare the relative effectiveness of different interventions (Dias et al. 2011). This method allows researchers to synthesize the results of trials that have evaluated the same health outcomes, but have used different treatments or interventions. Network meta-analysis provides a […]